CEL-SCI Announces Start of Multikine Phase III Study by Teva Pharmaceuticals Industries, Ltd. in Israel

CEL-SCI Corporation CVM announced today that its partner Teva Pharmaceuticals has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine®, the Company's flagship cancer immunotherapy. The first hospital is called Tel Aviv Sourasky Medical Center and is located in Tel Aviv, Israel. Patient enrollment is expected to start soon in this center. Teva plans to sign up another 2 Israeli clinical centers to conduct this study, which is already ongoing at multiple clinical sites in the United States, Canada, Poland, Hungary, Taiwan and India. The total study is expected to enroll about 880 head and neck cancer patients in over 40 hospitals in 9 countries. CEL-SCI's partner Orient Europharma will conduct parts of the Phase III study in Taiwan. Teva holds exclusive marketing rights to sell Multikine in Israel and Turkey. Geert Kersten, CEO of CEL-SCI said, ”We are pleased to partner with Teva for this pivotal study. Teva has significant experience and expertise in conducting clinical trials, and we are excited about the relationship we have established with the company as we conduct this Phase III trial. The trial is designed to demonstrate that Multikine represents a new paradigm in the treatment of head and neck cancer."